(C) PLOS One
This story was originally published by PLOS One and is unaltered.
. . . . . . . . . .



A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge [1]

['Courtney Woolsey', 'Department Of Microbiology', 'Immunology', 'University Of Texas Medical Branch', 'Galveston', 'Texas', 'United States Of America', 'Galveston National Laboratory', 'Robert W. Cross', 'Krystle N. Agans']

Date: 2022-07

Abstract Background Marburg virus (MARV), an Ebola-like virus, remains an eminent threat to public health as demonstrated by its high associated mortality rate (23–90%) and recent emergence in West Africa for the first time. Although a recombinant vesicular stomatitis virus (rVSV)-based vaccine (Ervebo) is licensed for Ebola virus disease (EVD), no approved countermeasures exist against MARV. Results from clinical trials indicate Ervebo prevents EVD in 97.5–100% of vaccinees 10 days onwards post-immunization. Methodology/Findings Given the rapid immunogenicity of the Ervebo platform against EVD, we tested whether a similar, but highly attenuated, rVSV-based Vesiculovax vector expressing the glycoprotein (GP) of MARV (rVSV-N4CT1-MARV-GP) could provide swift protection against Marburg virus disease (MVD). Here, groups of cynomolgus monkeys were vaccinated 7, 5, or 3 days before exposure to a lethal dose of MARV (Angola variant). All subjects (100%) immunized one week prior to challenge survived; 80% and 20% of subjects survived when vaccinated 5- and 3-days pre-exposure, respectively. Lethality was associated with higher viral load and sustained innate immunity transcriptional signatures, whereas survival correlated with development of MARV GP-specific antibodies and early expression of predicted NK cell-, B-cell-, and cytotoxic T-cell-type quantities. Conclusions/Significance These results emphasize the utility of Vesiculovax vaccines for MVD outbreak management. The highly attenuated nature of rVSV-N4CT1 vaccines, which are clinically safe in humans, may be preferable to vaccines based on the same platform as Ervebo (rVSV “delta G” platform), which in some trial participants induced vaccine-related adverse events in association with viral replication including arthralgia/arthritis, dermatitis, and cutaneous vasculitis.

Author summary Marburg virus (MARV) is one of the deadliest viruses known to man. One of the most effective vaccines against this pathogen uses a recombinant vesicular stomatitis virus (rVSV) platform to express MARV glycoprotein (GP) immunogen. As rVSV-based vaccines may be used as medical interventions to mitigate or prevent outbreaks of MARV, defining the time window needed to elicit protection is vital. Here, a rVSV vector expressing MARV glycoprotein (rVSV-N4CT1-MARV-GP) fully protected nonhuman primates from lethality and disease when given as soon as 1 week prior to exposure. At 5- and 3-days pre-exposure, partial protection (80% and 20% survival, respectively) was achieved. Vaccination with rVSV-N4CT1-MARV-GP appears to “jump-start” the immune system to allow sufficient time for MARV-specific adaptive responses to form. This fast-acting vaccine is based on a similar platform as Ervebo, the only FDA- and EMA-approved vaccine for preventing Ebola virus infection. The rVSV-N4CT1-MARV-GP vaccine features additional attenuations in the rVSV backbone that may contribute to a more acceptable safety profile in vaccinees, as Ervebo in some recipients induced vaccine-related adverse events including rashes and joint pain.

Citation: Woolsey C, Cross RW, Agans KN, Borisevich V, Deer DJ, Geisbert JB, et al. (2022) A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. PLoS Negl Trop Dis 16(5): e0010433. https://doi.org/10.1371/journal.pntd.0010433 Editor: Michael R. Holbrook, NIAID Integrated Research Facility, UNITED STATES Received: January 7, 2022; Accepted: April 19, 2022; Published: May 27, 2022 Copyright: © 2022 Woolsey et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: All relevant data are within the manuscript and its Supporting Information files. Funding: This study was supported by the Department of Health and Human Services, National Institutes of Health grant U19AI142785 to T.W.G. and UC7AI094660 for BSL-4 operations support of the Galveston National Laboratory. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: The rVSV vector described in this manuscript is the subject of a patent licensed to Auro Vaccines. C.G., T.E.H., M.A.E., J.H.E., and D.M. are paid employees of Auro Vaccines, LLC. Auro Vaccines in-licenses a portfolio of patents previously obtained from Wyeth to support the development of Vesiculovax vectors as vaccines against hemorrhagic fever viruses. The other authors have declared that no competing interests exist.

Introduction The genera Marburgvirus and Ebolavirus are members of the family Filoviridae that cause a similar life-threatening hemorrhagic disease in humans and nonhuman primates (NHPs) [1]. Due to their high risk to national security and public health, viruses in both genera are classified as World Health Organization (WHO) High Priority Category A pathogens [2] and US Centers for Disease Control (CDC) Tier 1 select agents [3]. While Ebolavirus contains six genetically distinct species, Marburgvirus contains a single species: Marburg marburgvirus (MARV). In 2004–2005, MARV was responsible for one of the deadliest filovirus outbreaks to date. The virus emerged in the Uige province of Angola resulting in 252 confirmed cases and 227 deaths (~ 90% case fatality rate) [4]. Outbreaks of MARV are primarily restricted to eastern and southern Africa, which largely overlaps with the geographic distribution of its reservoir species, the Egyptian fruit bat (Rousettus aegyptiacus) [5]. While MARV outbreaks have so far been limited and sporadic, field studies in Uganda indicate that 2–3% of Rousette bats are actively infected with Marburgviruses at any given time [6]. Biannual seasonal pulses contribute to a ~ 10% increase in MARV infections in juvenile Rousette bats that coincide with spillover into human populations [6]. This high rate of infection along with the extensive seroprevalence in Rousette bats underscore the underappreciated threat that MARV poses to public health. Marburgviruses have also recently emerged in previously non-endemic regions. On August 6th, 2021, the first known case of Marburg virus disease (MVD) in West Africa was reported to the World Health Organization [7]. The case originated in a villager from southwestern Guinea, not far from the Sierra Leonean and Liberian borders. Prior to the outbreak, surveillance in the region revealed evidence of filoviruses circulating in nearby Sierra Leone, with active MARV infection in approximately 2.5% of Rousette bats [8]. Virus sequences obtained from Rousette bats in this area were most genetically similar to human isolates identified during the deadly MARV-Angola outbreak (2005), as well as bat isolates in Gabon and the Democratic Republic of Congo (DRC) (2006–2009). This evidence highlights the importance of pathogen surveillance in these regions and stresses the need for medical countermeasures against MVD as spillover events will likely continue to occur. While substantial progress has been made towards the development of vaccines for one ebolavirus species, Zaire ebolavirus (EBOV), no licensed MVD vaccines or therapeutics are currently available. Ervebo is the only vaccine approved by both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) (https://www.ema.europa.eu/en/medicines/human/EPAR/ervebo) and is recommended by the WHO and US Advisory Committee on Immunization Practices (ACIP) for the prevention of Ebola virus disease (EVD) [9,10]. The vaccine is comprised of a live-attenuated, recombinant vesicular stomatitis virus (rVSV) vector that expresses EBOV glycoprotein (GP) immunogen instead of its native glycoprotein (G). Administration of Ervebo to contacts (and contacts of contacts) of confirmed cases in a ring vaccination trial during the 2013–2016 West Africa and 2018–2020 DRC EBOV outbreaks prevented disease in 97.5–100% of those immunized within 10 days onwards [11,12]. These data demonstrate the ability of Ervebo to serve as a fast-acting vaccine. To protect exposed individuals and reduce community transmission, a similar vaccination strategy could be implemented in the event of a MARV outbreak. Preclinical studies have demonstrated the use of rVSV vectors to serve as preventative vaccines and postexposure treatments against MVD in guinea pigs and nonhuman primates (NHPs) [13–21]. NHPs serve as the most stringent animal model for testing medical countermeasures and are considered the “gold standard” for recapitulating human manifestations of MVD including coagulopathies [22]. When administered ~ 1 month before challenge, a single dose of a rVSV vaccine expressing MARV GP fully protected NHPs against a 1000 PFU lethal challenge of various MARV variants [16,18,20]. Immunity with an rVSV vector was also durable with 100% protection against a lethal MARV exposure 14 months post-vaccination [23]. Moreover, all NHPs survived when the vaccine was administered 20–30 minutes post MARV (Musoke variant) exposure at the same challenge dose [15]. However, treatment with a rVSV vector at 20–30 minutes after infection failed to fully defend macaques against challenge with the Angola variant of MARV (only 25% survival) [14]. In vitro studies demonstrate the Angola variant enters host cells via C-type lectin receptors more efficiently than MARV-Musoke, which may contribute to its increased pathogenicity [24]. MARV-Angola also yields a more rapid disease course and a more pronounced pathology in outbred guinea pigs [25] and in NHPs [26], suggesting the Angola variant sets a high bar for MVD vaccines and therapeutics in terms of conferring protection. While preclinical studies have demonstrated the ability of rVSV-based vaccines to rapidly combat Marburgviruses including the Angola variant [13,14], the exact prophylactic window remains undefined. Recently, Marzi et al. reported that a “delta G” rVSV-based vaccine (rVSVΔG-MARV-GP-Angola) similar to Ervebo fully protected NHPs when vaccinated at 7 or 14 days prior to exposure [27]. Partial protection (75%) was observed when NHPs were vaccinated 3 days before exposure. Correspondingly, postexposure treatment with a similar vaccine at 20–30 minutes after infection was shown to be 89% effective in protecting NHPs against a low 50 PFU dose of MARV-Angola [13]. Although these results are promising, safety studies with the delta G Ervebo vector have shown undesirable vaccine-related adverse events in humans including prolonged and recurrent arthritis symptoms, maculopapular or vesicular dermatitis, cutaneous vasculitis, and viral shedding [28,29]. While Ervebo was deemed safe for human use and none of these adverse events were classified as contraindications, a highly effective but less reactogenic next generation vaccine would likely be preferred for widespread immunization. Highly attenuated rVSV-based Vesiculovax vaccines induce low reactogenicity in humans and exhibit fast-acting potential in NHPs [13,14,17,30]. When NHPs were administered rVSV-N2CT1-MARV-GP or rVSV-N4CT1-MARV-GP Vesiculovax vectors 20–30 minutes after a low dose MARV-Angola exposure (50 PFU), survival was 80% and 60%, respectively [13,14]. Therefore, Vesiculovax vaccines provide comparable protection as delta G vaccines. Unlike delta G rVSV vectors, Vesiculovax vectors express target antigen at the first genomic position from the single 3’ transcriptional promoter to increase immunogen expression [17]. The native G is preserved but contains a cytoplasmic tail truncation that interferes with particle maturation due to decreased interaction of G and the nucleoprotein (N) at the nucleocapsid core [31,32]. The rVSV-N4CT1-MARV-GP vaccine is a highly attenuated vector containing a rVSV N4 translocation (N2 vectors contain an N2 translocation). Shuffling the rVSV N from the first to the fourth gene markedly diminishes the intracellular abundance of this protein by virtue of its increased distance from the 3’-proximal promoter site [33]. These modifications enable robust attenuation of the vector while retaining high immunogenicity. In this study, we tested the ability of the highly attenuated rVSV-N4CT1-MARV-GP vector to serve as a rapid-acting vaccine for reactive immunization during MVD outbreaks. NHPs were vaccinated at 7, 5, or 3 days before exposure to define the minimum time needed between vaccination and challenge to elicit protective immunity against MARV-Angola. Samples were collected over the course of the study to examine NHPs for clinical signs of disease and to characterize the immune response to vaccination after challenge.

Methods Ethics statement Animal studies were conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals. All experiments adhered to principles stated in the eighth edition of the “Guide for the Care and Use of Laboratory Animals” (National Research Council, 2011). The Galveston National Laboratory (GNL) where this research was conducted (UTMB) is fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International and has an approved OLAW Assurance (#A3314-01). Animal studies were performed in BSL-4 biocontainment at the University of Texas Medical Branch (UTMB) and the protocol was approved by the UTMB Institutional Biosafety Committee. Generation of rVSV vaccine vectors The rVSV-N4CT1-MARV-GP and rVSVN4CT1-HIVgag vaccine vectors used in this study were recovered from infectious clones as described previously [14,17]. An expression cassette encoding the full-length MARV-Angola GP (accession number: DQ447653) or HIV gag protein, respectively, was cloned into a plasmid containing the full-length VSV genome. This plasmid encodes for a VSV N1 to N4 gene translocation and VSV G CT1 truncation; the MARV-Angola GP or HIV gag gene is expressed from the first genomic position from the single 3’-proximal promoter site to maximize GP antigen expression. Vectors were then recovered from Vero cells following electroporation with the resulting plasmids along with VSV helper plasmids. The rescued virus was plaque purified and amplified to produce virus seed stocks. Vaccine vectors were purified and concentrated for in vivo experiments. Before proceeding to in vivo studies in NHPs, the vector genomes were completely sequenced to verify the fidelity of the open reading frames (ORFs) for all genes. Challenge virus The MARV-Angola seed stock originates from the serum of a fatal patient (8-month-old female; isolate 200501379) during the 2004–2005 Uige, Angola outbreak (DQ: 447653.1). The p2 challenge material was created by passaging the original isolate 200501379 twice onto Vero E6 cells (titer 1.5 × 107 PFU/mL). Variant frequencies for our seed stock are provided as supplementary data (S1 Data). Maximum variances of our stock were found at noncoding positions A2834G and A8433G, but these mutations accounted for less than 10% and 7% of the virus population, respectively. All other LoFreq variants constituted less than 5% of the virus population. Notably, the consensus sequence of our virus seed stock was nearly identical (99.99%) to the parental sequence (DQ: 447653.1) except for a single mismatch in the noncoding trailer sequence (A19105T), and the seed stock is 100% identical to the reference sequence (GenBank: KR867677.1). Stocks were certified free of endotoxin (< 0.5 EU/mL) and mycoplasma contamination. Animal challenge Eighteen adult (9 females and 9 males) cynomolgus macaques (Macaca fascicularis) of Chinese origin (PreLabs, Worldwide Primates) ranging in age from 3 to 8 years and weighing 2.86 to 7.60 kg were used for three separate studies at the GNL. Macaques were immunized with a single 10 million PFU intramuscular (i.m.) injection of rVSV-N4CT1-MARV-GP at 7 (N = 5), 5 (N = 5), or 3 (N = 5) days prior to MARV exposure. Three animals were immunized with an identical dose of rVSVN4CT1-HIVgag at each respective time point to serve as non-specific controls. The inoculation was equally distributed between the left and right quadriceps. All macaques were challenged i.m. in the left quadriceps with a uniformly lethal 1000 PFU target dose of MARV-Angola (actual doses were 1475, 1475, and 1300 PFU, respectively). An internal scoring protocol was implemented to track disease progression in challenged animals. Animals were checked at least twice daily for scoring criteria such as behavior and posture/activity level (score of 0–9), appetite (score of 0–2), respiration (score of 0–9), and the presence of hemorrhagic manifestations (score of 0–9). Subjects that reached a clinical score ≥ 9 were promptly euthanized with a pentobarbital solution. Blood collection Blood was collected by venipuncture into EDTA and serum tubes pre-challenge and 3, 6, 10, 14, 21, and 28 DPI, or terminally. An aliquot of EDTA-treated whole blood (100 μl) was diluted with 600 μl of AVL inactivation buffer (Qiagen, Hilden, Germany), and RNA was extracted using a Viral RNA mini-kit (Qiagen) according to the manufacturer’s instructions. To isolate plasma and serum, tubes were spun at 2500 rpm for 10 minutes at 4°C. EDTA plasma and serum were stored at -80°C for analysis. Hematology and clinical chemistry Total white blood cell counts, white blood cell differentials, red blood cell counts, platelet counts, hematocrit values, mean cell volumes, mean corpuscular volumes, total hemoglobin concentrations, and mean corpuscular hemoglobin concentrations were analyzed from blood collected in tubes containing EDTA using a laser based hematologic analyzer (VetScan HM5). Serum samples were tested for concentrations of albumin, amylase, alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), aspartate aminotransferase (AST), glucose, total protein, cholesterol, total bilirubin (TBIL), creatinine (CRE), blood urea nitrogen (BUN), and C-reactive protein (CRP) by using a Piccolo point-of-care analyzer and Biochemistry Panel Plus analyzer discs (Abaxis). Viral load determination One-Step Probe RT-qPCR kits (Qiagen) and CFX96 system/software (BioRad) were used to determine viral copies in samples. To detect MARV RNA, we targeted the MARV NP gene with primer pairs and a 6-carboxyfluorescein (6FAM)–5′-CCCATAAGGTCACCCTCTT-3′–6 carboxytetramethylrhodamine (TAMRA) probe. Thermocycler run settings were 50 °C for 10 min; 95 °C for 10 s; and 40 cycles of 95 °C for 10 s plus 59 °C for 30 s. Integrated DNA Technologies synthesized all primers and Life Technologies customized the probes. Representative MARV genomes were calculated using a genome equivalent standard. The limit of detection for this assay is 1000 copies/ml. Infectious MARV loads were determined using a standard plaque assay. Briefly, increasing 10-fold dilutions of plasma samples were adsorbed to Vero E6 monolayers (ATCC Cat: CRL-1586) in duplicate wells (200 μl), overlaid with 0.8% agarose/2x EMEM, and incubated for six days at 37 °C in 5% CO2. Neutral red stain was added, and plaques were counted after a 24- to 48-hour incubation. The limit of detection for this assay is 25 PFU/ml. Immunohistochemistry Necropsies were performed on all subjects. Tissue samples of all major organs were collected for histopathologic and immunohistochemical (IHC) examination. Tissues were immersed in 10% neutral buffered formalin for at least 21 days, with an additional change of formalin, before removal from the BSL4 facility. Formalin-inactivated tissue samples were processed in a BSL1 facility. Tissue sections were subsequently deparaffinized and rehydrated through xylene and graded ethanol washes. Slides were processed for heat-induced antigen retrieval in a steamer at 95°C for 20 min in Sigma citrate buffer, pH 6.0, 10× (Sigma-Aldrich, St. Louis, MO). Slides went through heat antigen retrieval in a steamer at 95°C for 20 minutes in Sigma Citrate Buffer, pH6.0, 10x (Sigma Aldrich, St. Louis, MO). The tissue sections were processed for IHC using the Thermo Autostainer 360 (ThermoFisher, Kalamazoo, MI). Specific anti-Marburg NP immunoreactivity was detected using an anti-Marburg NP primary antibody at a 1:4000 dilution for 60 min. Secondary antibody used was biotinylated goat anti-mouse IgG (Vector Laboratories, Burlingame, CA #BA-9200) at 1:200 for 30 min followed by Vector Streptavidin Alkaline Phosphatase at a dilution of 1:200 for 20 minutes (Vector Laboratories #SA-5100). Slides were developed with Bio-Red (Biopath Laboratories, Oklahoma City, OK #BP-100-FR) for 7 min and counterstained with hematoxylin for 45 seconds. NanoString sample preparation Targeted transcriptomics was performed on blood samples from macaques as previously described [34]. NHPV2_Immunology reporter and capture probesets (NanoString Technologies) were hybridized with 5 μl of each RNA sample for ~24 hours at 65°C. The RNA:probeset complexes were then loaded onto an nCounter microfluidics cartridge and assayed using a NanoString nCounter SPRINT Profiler. Samples with an image binding density greater than 2.0 were re-analyzed with 2 μl of RNA to meet quality control criteria. Transcriptional analysis Briefly, nCounter.RCC files were imported into NanoString nSolver 4.0 software. To compensate for varying RNA inputs, an array of housekeeping genes and spiked-in positive and negative controls were used to normalize the raw read counts. The data was analyzed with NanoString nSolver Advanced Analysis 2.0 package to generate principal component (PC) figures, volcano plots, and cell-type trend plots. Human annotations were added for each respective mRNA to perform immune cell profiling within nSolver. Normalized data (fold-change- and p-values) were exported as a.CSV file and imported into GraphPad Prism version 9.3.1 to produce transcript heatmaps. These data are provided as supplemental data (S2 Data). To identify the functional annotation of individual transcripts, we interrogated the GeneCard database (https://www.genecards.org) [35]. For pathway analysis, functional enrichment of normalized counts was performed at the time of challenge, and early, mid, and late disease with Ingenuity Pathway Analysis (Qiagen). Z-scores were imported into GraphPad Prism version 9.3.1 to produce the canonical signaling heatmap. LoFreq variant identification The library for sequencing the challenge seed was prepared with an NEBNext Ultra II RNA Prep Kit (New England BioLabs, Inc.) following the manufacturer’s protocol. Briefly, ~100 ng of RNA was fragmented for 15 minutes, followed by cDNA synthesis, end repair, and adapter ligation. After 8 rounds of PCR, the resulting library was analyzed on an Agilent Bioanalyzer and quantified by qPCR. Samples were pooled and sequenced with a paired-end 75 base protocol on an Illumina (Illumina, Inc) NextSeq 550 using the High-Output kit. Reads were processed with Trimmomatic v0.36 [36] to remove low quality base calls and any adapter sequences. The de novo assembly program ABySS [37] was used to assemble the reads into contigs, using several different sets of reads, and kmer values from 20 to 40. Contigs greater than 400 bases long were compared against the NCBI nucleotide collection using BLAST. A nearly full-length MARV-Angola viral contig was obtained and all the remaining contigs mapped to either host cell ribosomal RNA or mitochondria. The trimmed reads from each sample were mapped to the sample consensus sequence BWA v0.7.17 [38] and visualized with the Integrated Genomics Viewer [39] to confirm a correct assembly. For single nucleotide variant and insertion/deletion calling the trimmed reads from each sample were mapped to the reference sequence, Sample 10, with BWA. The LoFreq version 2.1.3.1 [40] call and call-indels commands were used for variant calling, after the mapped reads were preprocessed with the LoFreq viterbi and indelqual commands to fix alignments at the read ends and insert indel quality scores, respectively. Variant calls were filtered at a level of 0.05%. Anti-MARV GP IgM and IgG ELISA MARV GP-specific IgM and IgG antibodies were quantified by ELISA on sera collected at the indicated blood collection days. Immunosorbent MaxiSorp 96-well plates were coated overnight with 15 ng/well (0.15mL) of recombinant MARV GPΔTM (ΔTM: transmembrane region absent; Integrated Biotherapeutics, Gaithersburg, MD) in a sodium carbonate/bicarbonate solution (pH 9.6). Antigen-adsorbed wells were subsequently blocked with 2% bovine serum antigen (BSA) in 1 x PBS for at least two hours. Sera were initially diluted 1:100 and then two-fold through 1:12800 in ELISA diluent (2% BSA in 1× PBS, and 0.2% Tween-20). After a one-hour incubation, cells were washed four times with wash buffer (1 x PBS with 0.2% Tween-20) and incubated for an hour with a dilution of horseradish peroxidase (HRP)-conjugated anti-rhesus IgM (1:2500) or IgG antibody (1:5000) (Fitzgerald Industries International, Acton, MA). SigmaFast O-phenylenediamine (OPD) substrate (Sigma; P9187) was added to the wells after four additional washes to develop the colorimetric reaction. The reaction was stopped with 3M sulfuric acid ~5 minutes after OPD addition and absorbance values were measured at a wavelength of 492nm on a Biotek Cytation 5. Absorbance values were determined by subtracting uncoated from antigen-coated wells at the corresponding serum dilution. End-point titers were defined as the reciprocal of the last adjusted serum dilution with a value ≥ 0.20. Statistical analysis Statistical analysis of viral load was carried out in GraphPad Prism version 9.3.1 (GraphPad, Software, Inc., La Jolla, CA) using a mixed-effects model with Geisser-Greenhouse correction and a Dunnett’s multiple comparisons test. A multiple hypothesis Benjamini-Hochberg false discovery rate (FDR) corrected p-value less than 0.05 was deemed significant for transcriptional analyses, unless otherwise stated. A Pearson correlation coefficient was employed to measure linear correlation between individual subject viremia levels and expression of specific DE transcripts.

Discussion In a prior study, we showed that a highly attenuated rVSV-based vector, rVSV-N4CT1-MARV-GP, administered 20–30 minutes postexposure to a low dose MARV-Angola challenge afforded partial protection (60% survival) of NHPs [14]. As an extension of this previous work, we determined the minimum time needed between immunization and exposure to fully protect NHPs against MVD. Here, vaccination of macaques with a single 10 million PFU dose of rVSV-N4CT1-MARV-GP one week prior to MARV-Angola challenge resulted in lack of detectable viremia in these animals with protection from clinical disease and lethality. [27]. However, we detected changes in bloodwork of surviving subjects indicative of very mild disease in the absence of clinical signs. Immunization at 5 or 3 days before exposure resulted in 80% and 20% survival, respectively. Thus, this highly attenuated Vesiculovax vector provided comparable protection (100% survival) as the delta G vector as a rapid vaccine when administered one week before exposure. Although higher survival was reported for the delta G vector when given -3 days pre-challenge; no statistically significant difference was found between the two vaccines (log rank test). Small group sizes used in the previous study make a direct comparison of vaccine efficacy difficult to interpret. Nevertheless, the fast-acting protection of rVSV-N4CT1-MARV-GP supports the use of Vesiculovax vaccines to combat future outbreaks of MVD. As a testament to this potential, ring vaccination with a similar EBOV-specific rVSV vector, Ervebo, reduced mortality and virus transmission during the 2013–2016 West Africa EBOV epidemic and 2018–2020 DRC EBOV outbreak [11,12]. While the Ervebo “delta G (rVSVΔG)” vaccine appears highly efficacious and durable [47], some undesirable vaccine-associated events have been reported in humans, particularly in individuals receiving high doses. Besides common vaccine reactions (injection site pain, fatigue, headache, muscle pain), these side effects included moderate to severe arthritis (with pain lasting a median of 8 days), postvaccination fever persisting for days, cutaneous vasculitis, and dermatitis manifesting as vesicular, maculopapular, or purpuric lesions distal to the inoculation site [28,29]. Recovery of virus from synovial fluid and skin vesicles confirmed dissemination of the vaccine vector in peripheral tissues. Lowering the dose of Ervebo reduced reactogenicity, but also decreased immunogenicity and did not prevent arthritis, dermatitis, or cutaneous vasculitis in vaccinees. Although replication of the vaccine vector likely contributes to the rapid protection achieved with Ervebo, high viral loads throughout the body raises concerns about the potential short- and long-term effects of the vaccine. For these reasons, Ervebo is primarily indicated for reactive vaccination of individuals at high risk of exposure. A vaccine with comparably efficacy but a safer profile would be preferred for widespread use. Indeed, a rVSV-N4CT1 vector expressing EBOV GP protein similarly protected NHPs from lethal EBOV challenge despite a high degree of attenuation [48,49] and was well tolerated and immunogenic in phase I clinical evaluation (https://clinicaltrials.gov/ct2/show/NCT02718469) [30]. The vaccine elicited robust EBOV GP-specific IgG responses in humans and modest but balanced cellular immune responses. Importantly, no incidents of vaccine shedding, arthritis, nor skin rashes were reported in vaccinees at any dose tested including individuals given a high 18 million PFU dose. Based on these results, we anticipate rVSV-N4CT1-MARV-GP can similarly serve as a safe, immunogenic, and effective vaccine against MVD suitable for both preventive and reactive immunization. The specific mechanisms of rapid rVSV-elicited protection are not fully elucidated but are thought to involve stimulation of both innate and adaptive immunity [13,27,50–52]. Resistance to disease was strongly tied to early control of MARV replication. On the day of challenge, specifically vaccinated survivors compared to fatal cases tended to express higher levels of transcripts associated with interferon and RIG-I signaling, indicating a robust innate response may be needed to shape protective immunity. In survivors, innate signaling promptly resolved after MARV exposure unlike fatal cases concurrently with an accumulation of adaptive immunity-related transcripts, particularly in earlier vaccinated subjects. Administration of a non-specific rVSVN4CT1-HIV-gag1 vector control did not appear to delay the time-to-death and resulted in complete lethality of macaques following exposure to MARV-Angola, indicating MARV GP-specific responses modulate host resistance to MVD. This hypothesis is supported by the lack of substantial antibody titers and the absence of adaptive signaling in vector control subjects. Conversely, MARV GP-specific IgM and IgG titers were detected in all specifically vaccinated survivors by 0–6 DPI, and increased transcriptionally derived B cell, cytotoxic cell, and Th1 cell predicted frequencies were detected in these subjects as early as the day of challenge. Thus, humoral and cellular immune responses directed at the GP correlate with survival as we have previously shown [13]. Fatal outcome in vaccinated subjects corresponded with dramatic upregulation of transcripts encoding pro-inflammatory IP-10 and neutrophil-associated S100A8 and S100A9, which were previous reported to correlate with EBOV lethality in humans [42,43] and in NHPs infected with Bundibugyo ebolavirus [34]. Similarly, lethality correlated with expression of immune checkpoint molecules as reported in other studies (LAG3 [13], CTLA4 [44]). Thus, certain factors associated with host susceptibility to MVD appear shared among various filovirus infections. The most significantly downregulated mRNA in vector control and vaccinated non-surviving subjects was complement factor D (CFD), a serine protease that cleaves complement factor B in the alternative complement pathway leading to downstream activation of the membrane attack complex [53]. As CFD is known to participate in opsonization and killing of pathogens, and viruses are commonly known to evade the complement system, this novel filovirus disease mechanism should be further explored. Our transcriptomic results revealed NK cells and cytotoxic T cells are strongly implicated in rVSV-N4CT1-MARV-GP-associated fast-acting protection. Transcripts encoding cytoplasmic granule components including perforin (PRF1), granzyme A (GZMA), granzyme B (GZMB), granzyme K (GZMK), and granzyme H (GZMH) were among the topmost upregulated molecules in vaccinated survivors. Not until late disease did we observe granzyme expression in fatal subjects. Activation of lymphocytes in non-survivors likely represents cytokine-mediated and not antigen-dependent T-cell activation as filovirus infection is known to interfere with antigen presentation [54,55], and these subjects exhibited high viral loads. Increased expression of transcripts encoding killer cell lectin-type receptors (KLRF1 (NKp80), KLRB1 (CD161), KLRD1 (CD94)) was also evident in surviving subjects. These receptors are ubiquitously expressed on NK cells and are involved in stimulation and regulation of cytotoxicity or self-nonself discrimination, further supporting this claim. Previously, we showed higher overall NK cell frequencies and recruitment of a specific subset (CD16+) of NK cells were important for postexposure protection against MVD with rVSVΔG and rVSV-N2CT1 vectors [13]. CD16+ CD8a+ NK cells in NHPs represent the equivalent of the highly cytotoxic CD56dim NK cell subset in humans [46]. These cells have limited cytokine-secreting potential but participate in killing virally infected cells or initiating antibody-dependent cell-mediated cytotoxicity (ADCC). Accordingly, depletion studies have revealed NK cell-intact mice survive longer after a mouse-adapted EBOV challenge, which is further enhanced by postexposure treatment with a rVSVΔG expressing EBOV GP (VSVΔG/EBOV GP) [56]. The authors of this study reported treatment with VSVΔG/EBOV GP treatment resulted in significantly higher NK cell-mediated cytotoxicity and IFN-γ secretion. Furthermore, recent research using a systems biology approach has identified NK cells as a primary correlate of antibody induction in humans receiving Ervebo. [51]. Specifically, the authors found that the frequency of CD56bright NK cells on day 3 postvaccination and the expression of CXCR6 on CD56dim NK cells on day 1 postvaccination positively correlated with antibody responses suggesting a potential role for antibody-mediated NK cell activation in vaccine-induced immune responses [57]. Thus, early NK cell differentiation status may dictate Fc-mediated activation of NK cells. This finding may be of relevance as antibody neutralizing capacity is not highly correlative of protection against MVD, and only low levels of neutralizing antibodies are typically detected following rVSV-MARV vaccination [13,27]. Previously, we’ve specifically measured the capacity of rVSV-N4CT1-MARV-GP to induce neutralizing antibodies against MARV [14]. Similar to previous reports [13,20], vaccinated animals produced only low levels of neutralizing antibody with PRNT 50 values ranging from 1:20 to 1:40 during the late convalescent period. Detectable neutralizing antibody for most vaccinees did not appear until after 10 DPI indicating direct virus neutralization is not critical for protection alone as this is beyond the typical time-to-death window for a 1000 pfu MARV-Angola challenge (6–8 DPI). Antibody neutralizing capacity and non-neutralizing antibody mechanisms were not assessed in this study, but future examinations should examine the role of ADCC and other Fc-mediated antibody effector functions in rVSV-N4CT1-MARV-GP-mediated protection against MVD. Other immune components may also confer rVSV-N4CT1-MARV-GP protection. Results from clinical trials showed VSVΔG/EBOV GP elicited GP-specific CTLs, follicular T helper cells, and IFN-γ-secreting T helper cells [52,58,59]. Not surprisingly, Tbet (TBX21), the lineage-defining transcription factor for Th1 cells [60], was one of the most significantly upregulated transcripts in survivors 3–10 DPI in this study. Th1 cells secrete IFN-γ and IL-2 and represent a lineage of CD4+ effector T cells that promote cell-mediated immunity and defense against intracellular pathogens. As we’ve previously reported, postexposure survival against MVD following rVSV vaccination corresponded with increased polyfunctional IFN-γ+ and IL-2+ MARV GP-specific Th1 cells [13]. Other effector functions of Tbet include promotion of 1) immunoglobulin class switching, 2) the terminal differentiation of CD8+ T cells, 3) the maturation of NK cells, and 4) the secretion of cytoplasmic granules such as granzymes. Additionally, Tbet can protect the host from amplification of aberrant innate responses by dampening type-I IFN transcription factors and IFN-stimulated genes [61], which are highly expressed after MARV-Angola infection [62] and corresponded with lethal outcome in this study. Our pathway analysis supported activation of T cell responses and simultaneous repression of pathways involved in pattern recognition receptor and interferon signaling in line with this reasoning. Based on these collective findings, we infer virus-specific cytotoxic and helper T cells, along with plasma cells and NK cells, likely play a key role in defense against MVD. While the molecular mechanisms involved in swift protection against MVD need additional clarification, we demonstrate that innate and adaptive immunity likely act in concert to elicit fast-acting protection. Further investigation is needed to determine how individual host responses to rVSV-N4CT1-MARV-GP vaccination alter susceptibility to MVD. In conclusion, the rapid protection mediated by rVSV-N4CT1-MARV-GP, along with promising safety and immunogenicity data from a phase I clinical evaluation with an analogous rVSV-N4CT1 vaccine, supports the testing of rVSV-N4CT1-MARV-GP in phase I clinical trials as the next step in developing an effective and safe vaccine against MARV. Future work will include an examination of the durability of immune responses induced by rVSV-N4CT1-MARV-GP, as long-lived protection is an important characteristic of any vaccine. Presently, our results indicate highly attenuated Vesiculovax vaccines may be suitable for ring vaccination during MVD outbreaks to save lives and reduce community transmission.

Supporting information S1 Fig. The topmost upregulated transcripts in Vesiculovax-vaccinated survivors on the day of challenge. Heatmap of the most upregulated mRNAs in survivor versus fatal subjects at five days post rVSV-N4CT1-MARV-GP vaccination (DPV) compared to 3 DPV. As only a single survivor exists in the 3 DPV group and a single fatal case exists in the 5 DPV group, statistical analysis was not performed. Red indicates high expression; blue indicates low expression; white indicates no difference in expression. Dots indicate whether specific mRNA is involved in adaptive immunity or innate immunity/interferon signaling. https://doi.org/10.1371/journal.pntd.0010433.s001 (EPS) S2 Fig. The topmost upregulated and downregulated transcripts in fatal vector control subjects. Heatmap of the most upregulated (A) and downregulated (B) mRNAs in vector control subjects at late disease. Red indicates high expression; blue indicates low expression; white indicates no difference in expression. Dots indicate whether specific mRNA is involved in adaptive immunity or innate immunity/interferon signaling. Abbreviations: E, early disease (3 DPI); M, mid disease (6 DPI); L, late disease (10 DPI or terminal timepoint). https://doi.org/10.1371/journal.pntd.0010433.s002 (EPS) S3 Fig. Transcriptional correlates associated with lethal outcome in Vesiculovax-vaccinated macaques exposed to MARV-Angola. Pearson correlation plots for calprotectin (S100A8 and S100A9) and immune checkpoint (LAG3 and CTLA4) transcripts (Benjamini-Hochberg false discovery rate (FDR) corrected p-value less than 0.05). https://doi.org/10.1371/journal.pntd.0010433.s003 (EPS) S4 Fig. Volcano plot depicting transcriptional changes in the vaccinated survivor versus fatal subjects in the -3 DPI vaccination group. (A) Shown is a volcano plot displaying -log10(p-values) and log2 fold changes for each mRNA target at late disease (10 DPI, or the terminal time point in fatal cases). Horizontal lines within the plot indicate adjusted p-value thresholds. Medium-dark blue dots denote mRNA targets with an adjusted p-value < 0.10; dark blue dots denote mRNA targets with an adjusted p-value ≤ 0.50; gray open dots denote mRNA targets with an adjusted p-value > 0.50. (B) Respective cell-type quantities for the vaccinated survivor (n = 1) and fatal (n = 5) cohorts at late disease (10 DPI, or the terminal time point in fatal cases) within the -3 DPI vaccination group. Abbreviations: DPI, days post infection. https://doi.org/10.1371/journal.pntd.0010433.s004 (EPS) S1 Table. Clinical findings in MARV-exposed cynomolgus macaques immunized with Vesiculovax vaccine 7 days prior to challenge. Macaques were immunized with a vector control (n = 1) or rVSV-N4CT1-MARV-GP vaccine at -7 DPI (n = 5). *Day after MARV challenge is in parentheses up to the 28 DPI study endpoint. †Fever is defined as a temperature greater than 2.5 °F above baseline, at least 1.5 °F above baseline and ≥ 103.5 °F, or 1.1 °F above baseline and ≥ 104°F. Leukopenia, thrombocytopenia, and lymphopenia are defined by a > 40% drop in numbers of leukocytes, platelets, and lymphocytes, respectively. Leukocytosis, monocytosis, and granulocytosis are defined as a ≥ two-fold increase in leukocytes, monocytes, and granulocytes, respectively. Crosses indicate increases in liver enzymes (ALT, AST, ALP, GGT) or renal function test values (BUN, CRE): 2- to 3-fold increase, +; >3- up to 5-fold increase, ++; >5-fold increase, +++. Abbreviations: M, male; F, female; kg, kilogram; PFU, plaque-forming units; MARV, Marburg virus; BUN, blood urea nitrogen; CRE, creatinine; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; CRP, c-reactive protein; DPI, days post infection. https://doi.org/10.1371/journal.pntd.0010433.s005 (DOCX) S2 Table. Clinical findings in MARV-exposed cynomolgus macaques immunized with Vesiculovax vaccine 5 days prior to challenge. Macaques were immunized with a vector control (n = 1) or rVSV-N4CT1-MARV-GP vaccine at -5 DPI (n = 5). *Day after MARV challenge is in parentheses up to the 28 DPI study endpoint. †Fever is defined as a temperature greater than 2.5 °F above baseline, at least 1.5 °F above baseline and ≥ 103.5 °F, or 1.1 °F above baseline and ≥ 104°F. Leukopenia, thrombocytopenia, and lymphopenia are defined by a > 40% drop in numbers of leukocytes, platelets, and lymphocytes, respectively. Leukocytosis, monocytosis, and granulocytosis are defined as a ≥ two-fold increase in leukocytes, monocytes, and granulocytes, respectively. Crosses indicate increases in liver enzymes (ALT, AST, ALP, GGT) or renal function test values (BUN, CRE): 2- to 3-fold increase, +; >3- up to 5-fold increase, ++; >5-fold increase, +++. Abbreviations: M, male; F, female; kg, kilogram; PFU, plaque-forming units; MARV, Marburg virus; BUN, blood urea nitrogen; CRE, creatinine; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; CRP, c-reactive protein; DPI, days post infection. https://doi.org/10.1371/journal.pntd.0010433.s006 (DOCX) S3 Table. Clinical findings in MARV-exposed cynomolgus macaques immunized with Vesiculovax vaccine 3 days prior to challenge. Macaques were immunized with a vector control (n = 1) or rVSV-N4CT1-MARV-GP vaccine at -3DPI (n = 5). *Day after MARV challenge is in parentheses up to the 28 DPI study endpoint. †Fever is defined as a temperature greater than 2.5 °F above baseline, at least 1.5 °F above baseline and ≥ 103.5 °F, or 1.1 °F above baseline and ≥ 104°F. Leukopenia, thrombocytopenia, and lymphopenia are defined by a > 40% drop in numbers of leukocytes, platelets, and lymphocytes, respectively. Leukocytosis, monocytosis, and granulocytosis are defined as a ≥ two-fold increase in leukocytes, monocytes, and granulocytes, respectively. Crosses indicate increases in liver enzymes (ALT, AST, ALP, GGT) or renal function test values (BUN, CRE): 2- to 3-fold increase, +; >3- up to 5-fold increase, ++; >5-fold increase, +++. Abbreviations: M, male; F, female; kg, kilogram; PFU, plaque-forming units; MARV, Marburg virus; BUN, blood urea nitrogen; CRE, creatinine; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; CRP, c-reactive protein; DPI, days post infection. https://doi.org/10.1371/journal.pntd.0010433.s007 (DOCX) S1 Data. MARV-Angola seed stock variant frequencies. https://doi.org/10.1371/journal.pntd.0010433.s008 (XLSX) S2 Data. Log2 fold-change- and p-values for MARV-exposed cynomolgus macaques immunized with Vesiculovax. https://doi.org/10.1371/journal.pntd.0010433.s009 (XLSX)

Acknowledgments The authors wish to thank the UTMB Animal Resource Center for husbandry support of laboratory animals. We wish to thank Drs. Kevin Melody and Abhishek Prasad (UTMB, Galveston, TX) for assistance with the animal experiments. We wish to thank Natalie Dobias (UTMB, Galveston, TX) for her excellent technical expertise in processing animal specimens for histopathology. We wish to thank Dr. Steven Widen (UTMB, Galveston, TX) for his assistance with sequencing our virus seed stock and providing the LoFreq variant data.

[END]
---
[1] Url: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0010433

Published and (C) by PLOS One
Content appears here under this condition or license: Creative Commons - Attribution BY 4.0.

via Magical.Fish Gopher News Feeds:
gopher://magical.fish/1/feeds/news/plosone/

You are viewing proxied material from magical.fish. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.